PPF Acquires Stake in Autolus Therapeutics, Expands Cell Therapy Pipeline
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
PPF Group, a Czech Republic-based investment firm, announced on Sept. 16, 2019 that it has acquired a 19.2% stake in Autolus Therapeutics, a London-based biopharmaceutical company specializing in next-generation T cell programming technologies.
Autolus, whose drug development is focused on precisely targeted, controlled, and highly active chimeric antigen receptor (CAR)-T cell products, is developing a pipeline of next-generation T cell therapies targeting both hematological cancers and solid tumors. The company’s lead program, AUTO1, is expected to enter a pivotal Phase II study in patients with adult relapsed or refractory acute B lymphocytic leukemia later in 2019 with an anticipated filing for marketing authorization in 2021.
With investments in both Autolus and a majority-owned biotechnology company, SOTIO, also based in the Czech Republic, PPF aims to become a fully integrated oncology specialty pharma company. With SOTIO, PPF has built a biotechnology portfolio through in-house R&D, investments, acquisitions, and in licensing of products with companies like NBE-Therapeutics, Cellestia Biotech, Cytune Pharma, and Lead Discovery Center. SOTIO is developing a proprietary dendritic cell-based cell therapy platform (DCVAC) and has significant manufacturing and regulatory expertise in the domain of cellular therapies. SOTIO also recently initiated a Phase I/Ib clinical trial with its interleukin-15 superagonist, SO-C101.
“We are very excited by our investment into Autolus. The data published by Autolus on their CAR-T programs is very promising and their long-term ambitions are a perfect match with PPF’s strategy in healthcare,” said Ladislav Bartonicek, shareholder of PPF responsible for the biotechnology sector, in a company press release. “Our investment in Autolus confirms the long-term commitment of PPF and SOTIO to build a strong biotechnology portfolio developing a broad range of its own oncology products and investing in various biotech companies with promising new therapies.”
Source: PPF Group
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
